REHOVOT, Israel, July 27, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived
protein therapeutics company focused on orphan indications, announced today that it will release financial results for the second
quarter ended June 30, 2017 prior to the open of the U.S. financial markets on Tuesday, August 1.
Kamada management will host an investment community conference call on Tuesday, August 1 at 8:30am Eastern Time
to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by
dialing 888-221-9591 (from within the U.S.), 1 80 924 6042 (from Israel), or 719-325-4893 (International) and entering the
conference identification number: 2753969. The call will also be webcast live on the Internet on the Company’s website at www.kamada.com.
A replay of the call will be accessible two hours after its completion through August 15 by dialing 844-512-2921
(from within the U.S.) or 412-317-6671 (from outside the U.S.) and entering the conference identification number: 2753969. The call
will also be archived for 90 days on the Company’s website at www.kamada.com.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial
product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for
the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid
form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered
therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s
flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S.
Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter
International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors. In
addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that
are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin
America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of
AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trial in Europe. Kamada has also completed its
Phase 2 clinical trial in the U.S. for the treatment of AAT deficiency using our proprietary inhaled AAT. In addition, Kamada's
intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection.
Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10
pharmaceutical products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as
statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of
clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada’s current knowledge and its
present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual
results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of
several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA
approval process, additional competition in the AATD market or other markets in which Kamada operates or intends to operate, or
further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada
undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except
as otherwise required by law.
CONTACTS: Gil Efron Deputy CEO & Chief Financial Officer IR@kamada.com Bob Yedid LifeSci Advisors, LLC 646-597-6989 Bob@LifeSciAdvisors.com
